Ozbun M A, Medina D, Butel J S
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030.
Cell Growth Differ. 1993 Oct;4(10):811-9.
The phenotypes of p53 mutations found in human and murine tumors often are analyzed using a variety of transformation assays in vitro, but data have not been available to correlate in vitro effects with in vivo activities. We have assessed the effects of p53 mutations using mouse mammary epithelial cell lines which can be analyzed both in vitro and in vivo. Parental mammary epithelial cell lines (FSK series) injected into cleared mammary fat pads of syngeneic mice frequently give rise to preneoplastic lesions (HAN) which can be reestablished in culture (TM lines) to permit analysis of genetic changes important in the development of preneoplasia. Characterization of the FSK3 cell line revealed a cell population mixed with respect to p53 genotypes. One subpopulation of mutant (Ser233-234) p53-expressing cells was selected in a preneoplastic mammary outgrowth in vivo (TM3), whereas another minor population of mutant (Pro135) p53-expressing cells was selected during culturing of FSK3 cells in vitro. When FSK3 cells were subdivided and passaged in parallel in vitro, p53 genotypes continued to evolve and diverge. These findings reveal that selective pressures exerted on mammary epithelial cell populations in vivo are different from pressures present in vitro. Selective forces may vary from one cell culture environment to another. The growth advantage conferred by a specific p53 mutation appears to differ in vivo versus in vitro. We propose that caution should be exercised when attempting to correlate the effects of p53 mutations assayed in cell culture systems with the in situ phenotypes of mutant p53 in cancer.
在人和鼠类肿瘤中发现的p53突变的表型,通常使用多种体外转化试验进行分析,但尚无数据可将体外效应与体内活性相关联。我们使用可在体外和体内进行分析的小鼠乳腺上皮细胞系评估了p53突变的效应。将亲代乳腺上皮细胞系(FSK系列)注射到同基因小鼠清除后的乳腺脂肪垫中,常常会产生癌前病变(HAN),这些病变可在培养中重建(TM系),以便分析癌前病变发展过程中重要的基因变化。对FSK3细胞系的表征显示,其细胞群体在p53基因型方面是混合的。在体内的癌前乳腺增生中选择了一个表达突变型(Ser233 - 234)p53的细胞亚群(TM3),而在FSK3细胞的体外培养过程中选择了另一个表达突变型(Pro135)p53的细胞小群体。当FSK3细胞在体外进行细分并平行传代时,p53基因型继续进化并分化。这些发现表明,体内施加于乳腺上皮细胞群体的选择压力与体外存在的压力不同。不同的细胞培养环境中选择力可能有所不同。特定p53突变赋予的生长优势在体内和体外似乎有所不同。我们建议,在试图将细胞培养系统中检测到的p53突变效应与癌症中突变p53的原位表型相关联时应谨慎行事。